Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
The European oncology society's 2023 guideline for bile duct and gallbladder cancer, covering how the diseases are diagnosed, staged, operated on, treated with drugs and followed up.
Overview
ESMO Clinical Practice Guideline for biliary tract cancer, published in Annals of Oncology in 2023 by Vogel, Bridgewater, Edeline and colleagues for the ESMO Guidelines Committee. Europe PMC indexes no abstract for this article, so OnCo carries no figures from it; the guideline itself is open on the ESMO website and covers diagnosis, molecular testing, resection and adjuvant capecitabine, first-line gemcitabine-cisplatin with durvalumab, and later-line targeted options.
- No abstract is indexed on Europe PMC; recommendations are read from the guideline itself.
This is the reference European standard against which UK and NHS practice for gallbladder cancer is compared; it treats gallbladder cancer within biliary tract cancer rather than as its own disease.
- Gallbladder cancer recommendations are largely extrapolated from mixed biliary trials.
- Published before the zanidatamab approvals of 2024 and 2025.
Similar pages
not linked directly; found by shared links- Key paperSecond-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Shares Juan W. Valle, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-evidence.
- Key paperDurvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
Shares Juan W. Valle, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-evidence.
- Key paperHER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Shares Juan W. Valle, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (all types), Gallbladder cancer and the tag gallbladder-evidence.
- Key paperLiposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
Shares Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
- Key paperReal-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer
Shares Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
- Key paperDetecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection
Shares Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
- Key paperCarcinoma of the gallbladder: staging, treatment, and prognosis
Shares Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer and the tag gallbladder-evidence.
- Key paperSystematic review of management of incidental gallbladder cancer after cholecystectomy
Shares Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer and the tag gallbladder-evidence.